Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans

Completed · Phase 4 · Has a placebo group

Conditions studied: Type 2 Diabetes, Obesity

In brief

Obesity is a heightened state of inflammation in which production of cytokines and matrix metalloproteinases (MMPs) result in loss of function of insulin receptors and insulin resistance. Doxycycline (DOX) is a potent MMP inhibitor. We hypothesize that DOX will enhance insulin sensitivity and decreases inflammation in obese participants with type 2 diabetes (DM2).

Key facts

Study ID
NCT01375491
Run by
University of California, San Diego
People needed
39
Starts
2009-10-01
Expected to finish
2011-06-01
Last updated by the study team
2020-01-13

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.